Pipeline· July 22, 2026 · 17 min read
Antibody-Drug Conjugate (ADC) Clinical Trials by the Numbers (2026)
By Ran Chen#ADC#Oncology#Clinical Trials
Topic
Breast Cancer
Breast cancer drug access, ER+/HER2− targeting, biomarker-driven therapy, companion diagnostics, and oncology coverage workflows.
Approvals· July 16, 2026 · 19 min read
Revtorpyk (gedatolisib) coverage: breast cancer approval and billing
By Ran Chen#Oncology#Breast Cancer#FDA Approval
Pricing & Access· July 8, 2026 · 22 min read
Gilead Sciences Portfolio Dossier: The Biktarvy Cliff, Yeztugo PrEP, and an Oncology Reset
By Ran Chen#HIV PrEP#Generic Entry#Drug Pricing
Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Pricing & Access· May 30, 2026 · 11 min read
Datroway TNBC coverage guide: TROP2 ADC access and coding
By Ran Chen#ADC#Breast Cancer#Prior Authorization
Pricing & Access· May 27, 2026 · 9 min read
Trodelvy access guide for breast cancer coverage
By Ran Chen#Oncology#ADC#Prior Authorization
Pricing & Access· May 26, 2026 · 7 min read
Veppanu coverage guide for ER+/HER2- breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic